MetaVia (MTVA) investor relations material

Scientific rationale and program updates

• DA-1726 is a GLP-1/glucagon dual agonist with a unique 3:1 balance, aiming for superior glucose control and fat loss in obesity and type 2 diabetes patients.

• Phase I data for DA-1726 up to 32 mg showed strong glucose control and over 4% weight loss in four weeks, with a favorable safety profile.

• DA-1241 is an oral GPR-119 agonist that increases natural GLP-1 production and has direct hepatic effects, with Phase IIA data showing compelling results in presumed NASH patients.

• DA-1241 demonstrated an excellent safety profile in a 16-week Phase IIA study, supporting further development and potential expansion to other indications.

Differentiation and competitive landscape

• DA-1726's 3:1 GLP-1/glucagon ratio is designed to optimize efficacy and tolerability, differentiating it from competitors like pemvidutide and retatrutide.

• The ongoing 48 mg cohort for DA-1726 aims to achieve around 7% weight loss in eight weeks, with a focus on safety and efficacy without titration.

• DEXA and FibroScan assessments are being used to evaluate fat loss, lean mass, and liver effects, targeting both obesity and NASH populations.

• DA-1241 is positioned for combination strategies, especially with FGF21 analogues, to address the complex NASH landscape across fibrosis stages.

Strategic outlook and partnerships

• Plans include advancing DA-1726 to Phase II, with a focus on longer studies, more patients, and key endpoints like HbA1c and liver health.

• Active pursuit of partnerships and collaborations, especially with companies seeking differentiated assets in obesity and NASH.

• DA-1241's strategy centers on combination therapies, with ongoing discussions for collaborations, ideally with partners close to approval.

• AI-driven research with Syntekabio is accelerating indication expansion for DA-1241, aiming to identify new uses within months.